Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RSN0402
- Development stage
- Phase 1
- Lead developer
- Resproly
- Modality
- Small Molecules
- Administration
- Inhalation
01
Overview
RSN0402 is a small molecule investigational drug developed by Shenzhen Resproly Biopharmaceutical for the treatment of idiopathic pulmonary fibrosis (IPF). It is classified as an antifibrotic agent, though its precise mechanism of action remains undefined. The drug is being developed as an inhaled powder formulation, aiming to deliver targeted therapy directly to the lungs and reduce systemic side effects compared to oral antifibrotics. Preclinical studies have shown that RSN0402 was safe, well tolerated, and significantly reduced lung fibrosis and inflammation. As of July 2024, it is in phase 1 clinical trials in Australia for IPF[1][5][8].
- Other names
- RSN0402RSN-0402RSN 0402
Beyond the preview
Go deeper on RSN0402.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RSN0402.